Ticker: FDMT

Snapshot - 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) Short version: 4D (NASDAQ: FDMT) is accelerating its lead ophthalmology program (4D‑150) into Phase 3 while funding needs and burn rise. Cash + marketable securities total about $417.0M at 6/30/2025, management says this supports operation...